ARS Pharmaceuticals Inc News - SPRY

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for...

Form 8-K - Current report

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products ARS...

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical...

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

JJPK 2 months ago

Trading like news is eminent

👍️0

stocksrising 3 months ago

I’m In!! Going long, and selling naked Nov 12.5 puts ( almost $2 per put) GLTA

👍️0

EnchantedTitan62 3 months ago

Good call on the inhalent, last week FDA approved. Moving up again today. 👍

👍️ 1

JJPK 5 months ago

Close to 3mil shares traded in the last minute of trading.
Whats Up.??

👍️0

Monksdream 7 months ago

SPRY under $10

👍️0

erik007tc 7 months ago

I believe the fda review/approval will be within 6 months.

👍️ 1

Monksdream 8 months ago

SPRY over $10
Next day settlement begins 5/28 per SEC mandate

👍️0

dodgerdog 8 months ago

Good News around the corner? 🙂

👍️ 1 🤑 1

gail 1 year ago

ah, should have held, lol

👍️0

gail 1 year ago

not in as i hopped in something else, but watching now.

👍️0

Pt3 1 year ago

It not going up anytime soon but down Fda denied news

i grabbed some today too.

👍️0

makinezmoney 1 year ago

$SPRY:: Fabulous dump down to $2.60 here...............................

OKkkkkkkkkkkkkkkkkkkk.......... lets gooooooooooooooo

GO $SPRY

👍️0

MiamiGent 2 years ago

SPRY Also in ...
ARS PHARMACEUTICALS INC
Pre-market the price per share is $7.85 +$0.10 (1.29%)

https://stockcharts.com/h-sc/ui?s=SPRY

Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $17 Price Target
BENZINGA
8:34 AM ET May-18-2023
Wedbush analyst Andreas Argyrides reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and maintains $17 price target.

👍️0

MiamiGent 2 years ago

SPRY This is spraying profits all over my screen this morning! I have a very green screen! What's going on, I'm trying to glean.

https://stockcharts.com/h-sc/ui?s=SPRY

👍️0

MiamiGent 2 years ago

SPRY $8.32 +$0.28 (+3.483%)
Moving up after waffling this morning
Volume
2,403,836
90 Day Avg. Vol.
927,230

https://stockcharts.com/h-sc/ui?s=SPRY

👍️0

	Real-time Prices	Level 2
American Stock Exchange
Dow Jones Indices
NASDAQ
New York Stock Exchange
OTCBB
OTCMarkets
Precious Metal
OPRA
OPRA Indices
Forex

	Real-time Prices	Level 2
Dow Jones Indices
OTCBB
New York Stock Exchange
NASDAQ
American Stock Exchange
OTCMarkets
Precious Metal

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ARS Pharmaceuticals Inc (SPRY)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SPRY News

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

SPRY Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ARS Pharmaceuticals Inc (SPRY) News

ARS Pharmaceuticals Inc (SPRY)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SPRY News

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

SPRY Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%